Lipocine Earnings Call Transcripts
Fiscal Year 2026
-
LPCN 1154, an oral brexanolone for postpartum depression, showed rapid, durable, and clinically meaningful symptom improvement in subgroup analyses after excluding data from an outlier site. The drug demonstrated a favorable safety profile, rapid onset, and potential advantages over current treatments, supporting a streamlined regulatory path and broader market potential.
-
Phase III results for a postpartum depression treatment showed rapid, significant efficacy in key subgroups when excluding an anomalous site, with a strong safety profile and clear differentiation from current therapies. Sufficient funding is in place for a new trial, with interim results expected by late Q1 next year.
Fiscal Year 2025
-
LPCN 1154, an oral brexanolone for postpartum depression, is in phase III trials and aims to provide rapid, 48-hour outpatient relief with a strong safety profile. The FDA has agreed a single phase III study will suffice for NDA submission, targeted for mid-2026.
-
Two lead oral therapies are advancing: 2401 for obesity management, with a phase II trial starting Q3 and data expected late Q1 next year, and 1154 for postpartum depression, in phase III with NDA filing projected in about a year. Cash runway extends at least 12 months.
Fiscal Year 2024
-
LPCN2401, an oral androgen receptor agonist, demonstrated improved body composition by reducing fat and increasing lean mass in obese men, with additional benefits when combined with vitamin E. The therapy was well-tolerated, with a favorable safety profile and potential for use alone or with GLP-1 agonists to address lean mass loss.